Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?
Crossref DOI link: https://doi.org/10.1007/s00345-014-1406-2
Published Online: 2014-09-27
Published Print: 2015-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Merseburger, Axel S.
Hammerer, Peter
Rozet, Francois
Roumeguère, Thierry
Caffo, Orazio
da Silva, Fernando Calais
Alcaraz, Antonio
License valid from 2014-09-27